F.d.e.c.a Pharmaceutical Import Profile — Ecuador (DGFT 2022–2026)

Name: F.d.e.c.a Pharmaceutical Import Records from India — 2 Products, $380.6K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

F.d.e.c.a — Pharmaceutical Importer Profile (2026) | 2 Products, $380.6K Trade | TransData Nexus

Who Are the Verified Indian Suppliers to F.d.e.c.a?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Caritas Healthcare Private Limited	$5.2M	227	100.0%

F.d.e.c.a sources from 1 verified Indian supplier across 175 distinct formulations. The sourcing is highly concentrated — Caritas Healthcare Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does F.d.e.c.a Import?

Formulation	Value	Ships
Pharmacuiticals finished product	$200.0K	4
Pharmacuiticals finished product	$150.0K	3
Finished pharamceutical product - tacrolimus capsual 1MG - tacrocord 1MG	$150.0K	3
Finished pharamceutical product-atorvastatin tablets 40MG b.no.egt250058	$125.4K	3
Pharmacuiticals finished product amphotericin b lipid complex injection intravenous (50MG/10ML)	$100.0K	2
Finished pharamceutical product -iron sucrose injection 100 MG/5 ML INJ batch nois25002e is25003e mfg date feb-25 exp	$100.0K	2
Finished pharamceutical product - carvedilol tablets 12.5MG batch no. emv250362emv250370 emv250371 emv250372a	$100.0K	2
Urea cream BP 5% w/w batch no.g2339,g2340,g2341,g2347,g2338,g2342,g2344,g2345,g2346	$68.8K	3

F.d.e.c.a imports 175 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

What Products Does F.d.e.c.a Import?

Top Products by Import Value

1Methylprednisolone$342.0K 2Digoxin$38.7K

F.d.e.c.a Therapeutic Categories — 2 Specializations

F.d.e.c.a imports across 2 therapeutic categories, with Corticosteroids (89.8%), Cardiovascular (10.2%), representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Corticosteroids

1 products · 89.8% · $342.0K

Cardiovascular

1 products · 10.2% · $38.7K

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Methylprednisolone	Corticosteroids	$342.0K	7	1.2%	12
2	Digoxin	Cardiovascular	$38.7K	2	1.8%	7

Key Metrics

Total Import Value$380.6K

Products2

Shipments9

Categories2

CountryEcuador

#1 Rankings0

Indian Suppliers1

Formulations175

Top Categories

Corticosteroids89.8%

Cardiovascular10.2%

Last updated: March 28, 2026

F.d.e.c.a — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

F.d.e.c.a is a pharmaceutical importer based in Ecuador, specializing in the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company plays a pivotal role in the Ecuadorian pharmaceutical distribution network, ensuring the availability of essential medications to meet the country's healthcare needs. While specific details about its headquarters, parent company, and organizational structure are not publicly disclosed, F.d.e.c.a's operations are integral to the importation and distribution of pharmaceutical products within Ecuador.

2Distribution Network

F.d.e.c.a's distribution network encompasses multiple warehouse locations strategically situated across Ecuador to facilitate efficient logistics and timely delivery of pharmaceutical products. The company's logistics capabilities are tailored to meet the stringent requirements of the pharmaceutical industry, ensuring compliance with health regulations and maintaining the integrity of the products during transit. F.d.e.c.a's geographic coverage extends throughout Ecuador, enabling it to serve a wide range of healthcare facilities, including hospitals, clinics, and pharmacies, thereby contributing to the accessibility of quality medications nationwide.

Supplier Relationship Intelligence — F.d.e.c.a

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

F.d.e.c.a's sourcing strategy exhibits a high degree of concentration, with a total import value of $381,000 USD from India over nine shipments, focusing on two primary products: Methylprednisolone and Digoxin. This concentrated sourcing approach indicates a strategic choice to establish a reliable supply chain with a single supplier, CARITAS HEALTHCARE PRIVATE LIMITED, which has been the sole supplier for all shipments. The consistent partnership with CARITAS HEALTHCARE PRIVATE LIMITED suggests a stable and dependable relationship, reducing the complexities associated with managing multiple suppliers. However, this single-source dependency also presents a potential risk; any disruptions in CARITAS HEALTHCARE PRIVATE LIMITED's operations could directly impact F.d.e.c.a's ability to meet market demand.

2Supply Chain Resilience

F.d.e.c.a's supply chain resilience is closely tied to its exclusive partnership with CARITAS HEALTHCARE PRIVATE LIMITED. The lack of backup suppliers means that any operational challenges faced by CARITAS HEALTHCARE PRIVATE LIMITED—such as production delays, quality control issues, or logistical disruptions—could significantly affect F.d.e.c.a's ability to supply products to the Ecuadorian market. The limited diversity in imported formulations, with only 175 unique formulations, further constrains the company's ability to adapt to changes in market demand or supply chain disruptions. Additionally, the reliance on a single supplier may expose F.d.e.c.a to risks related to geopolitical factors, regulatory changes, or economic conditions affecting CARITAS HEALTHCARE PRIVATE LIMITED's operations.

3Strategic Implications

F.d.e.c.a's concentrated sourcing strategy positions the company to benefit from streamlined operations and potentially favorable terms with CARITAS HEALTHCARE PRIVATE LIMITED. This approach can lead to cost efficiencies and a simplified supply chain management process. However, the heavy reliance on a single supplier also exposes F.d.e.c.a to significant risks. Any disruptions in CARITAS HEALTHCARE PRIVATE LIMITED's operations could lead to supply shortages, impacting F.d.e.c.a's ability to meet market demand and potentially affecting its reputation and customer trust. For Indian exporters, this sourcing pattern presents an opportunity to become alternative suppliers to F.d.e.c.a, thereby diversifying the company's supply chain and mitigating associated risks.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Ecuador — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Ecuador

1Regulatory Authority & Framework

In Ecuador, the National Agency for Regulation, Control, and Sanitary Surveillance (ARCSA) is the primary regulatory body overseeing the pharmaceutical sector. ARCSA is responsible for ensuring that all pharmaceutical products, including those imported by companies like F.d.e.c.a, meet the required safety, efficacy, and quality standards. The regulatory framework governing pharmaceutical imports in Ecuador includes the Organic Law of Health, which outlines the requirements for the registration, control, and surveillance of medicines. Additionally, the Andean Community's regulations, to which Ecuador is a member, provide guidelines for the harmonization of pharmaceutical standards and facilitate the importation process within member countries.

2Import Licensing & GMP

Import licensing in Ecuador requires that all pharmaceutical products obtain a sanitary registration certificate from ARCSA before they can be legally imported and marketed. This process ensures that imported medicines comply with national health standards. Good Manufacturing Practices (GMP) certification is also mandatory for pharmaceutical products entering Ecuador. Ecuador recognizes GMP certificates from reputable international bodies, including the World Health Organization (WHO) and the European Union (EU). Importers like F.d.e.c.a must ensure that their suppliers hold valid GMP certifications from recognized authorities to facilitate the importation process and ensure product quality.

3Quality & Labeling

Ecuador's pharmaceutical regulations mandate that all imported medicines undergo batch testing to verify their quality, safety, and efficacy. Stability studies are also required to ensure that products maintain their intended quality throughout their shelf life. Labeling requirements stipulate that all information be presented in Spanish, including the product's name, dosage form, strength, batch number, expiration date, and storage conditions. Additionally, the National Agency for Regulation, Control, and Sanitary Surveillance (ARCSA) requires the implementation of a Unique Traceability Code (CUT) for medicines and medical devices. This code must be printed using a two-dimensional barcode on the packaging and placed in a visible location, facilitating the tracking and verification of pharmaceutical products throughout the supply chain.

4Recent Regulatory Changes

In January 2025, ARCSA issued Resolution ARCSA-DE-2024-058-DASP, enacting new technical regulations for the registration, control, and surveillance of general-use medicines. These regulations, which came into force on June 30, 2025, align with Ecuador's constitutional mandate to guarantee access to safe, effective, and high-quality medicines. The resolution emphasizes compliance with international standards set by the World Health Organization (WHO) and the Andean Community (CAN). Key highlights include mandatory registration of all pharmaceuticals intended for human use, ensuring that imported medicines meet stringent quality and safety standards.

TransData Nexus Research · Ecuador regulatory databasesMar 2026

F.d.e.c.a — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

F.d.e.c.a's focus on importing corticosteroids and cardiovascular medications, specifically Methylprednisolone and Digoxin, indicates a strategic alignment with prevalent health conditions in Ecuador. Corticosteroids are commonly used to treat inflammatory and autoimmune disorders, while cardiovascular drugs are essential for managing heart-related conditions. The market demand for these therapeutic areas is driven by the high incidence of chronic diseases such as arthritis, asthma, hypertension, and heart failure in the Ecuadorian population. By concentrating on these categories, F.d.e.c.a addresses critical healthcare needs, ensuring the availability of vital medications to improve patient outcomes.

2Sourcing Profile

F.d.e.c.a's sourcing strategy is centered on importing generic drugs from India, focusing on specific formulations that align with the therapeutic needs of the Ecuadorian market. The company's preference for finished pharmaceutical formulations, rather than raw Active Pharmaceutical Ingredients (APIs), suggests a streamlined approach to procurement, emphasizing ready-to-use products that meet established quality standards. India's robust pharmaceutical manufacturing sector, known for its adherence to international GMP standards, positions it as a reliable source for high-quality generic medications. This sourcing strategy enables F.d.e.c.a to provide cost-effective and accessible treatment options to the Ecuadorian healthcare system.

3Market Positioning

Based on its product mix, F.d.e.c.a primarily serves the hospital and wholesale distribution segments of the Ecuadorian pharmaceutical market. The focus on corticosteroids and cardiovascular medications aligns with the needs of healthcare facilities that manage a high volume of patients requiring these treatments. By ensuring a steady supply of essential medications, F.d.e.c.a supports the operational needs of hospitals and clinics, contributing to the overall efficiency and effectiveness of healthcare delivery in Ecuador.

TransData Nexus Research · DGFT trade data analysisMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: F.d.e.c.a identified across shipments using consignee name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as F.d.e.c.a's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 9 individual customs records matching F.d.e.c.a.
5.Supplier Verification: F.d.e.c.a sources from 1 verified Indian suppliers across 175 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

2 Products Tracked

2 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

F.d.e.c.a

F.d.e.c.a — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to F.d.e.c.a?

What Formulations Does F.d.e.c.a Import?

What Products Does F.d.e.c.a Import?

Top Products by Import Value

F.d.e.c.a Therapeutic Categories — 2 Specializations

Import Portfolio — Top 2 by Import Value

Key Metrics

Top Categories

F.d.e.c.a — Corporate Profile & Information

1Company Overview

2Distribution Network

Indian Suppliers

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — F.d.e.c.a

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into Ecuador — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

F.d.e.c.a — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to F.d.e.c.a

1Opportunity Assessment

2Requirements & Qualifications

Frequently Asked Questions — F.d.e.c.a

What products does F.d.e.c.a import from India?

Who supplies pharmaceuticals to F.d.e.c.a from India?

What is F.d.e.c.a's total pharmaceutical import value?

What therapeutic categories does F.d.e.c.a focus on?

Get Full F.d.e.c.a Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology